<DOC>
	<DOCNO>NCT02622581</DOCNO>
	<brief_summary>Open , non-interventional , prospective , multi-center clinical research platform main objective ass molecular biomarker testing , treatment outcome patient advance metastatic NSCLC Germany</brief_summary>
	<brief_title>Clinical Research Platform Into Molecular Testing , Treatment Outcome Non-Small Cell Lung Carcinoma Patients</brief_title>
	<detailed_description>Thorough knowledge treatment reality , e.g . characteristic , diagnostic , treatment outcome unselected patient real-life practice , crucial evaluate improve quality care patient metastatic non-small cell lung cancer ( NSCLC ) . The purpose CRISP set national clinical research platform document uniform data molecular testing , treatment , course disease patient advance metastatic NSCLC amenable curative treatment . A particular focus molecular biomarker test patient start first-line treatment . The data shall use assess current state care develop recommendation concern topic could improve . PRO assessment provide large-scale data quality life anxiety/depression real-life patient routine practice . In addition , two questionnaire ( concern individual quality life patient-caregiver communication ) validated German patient metastatic NSCLC . Furthermore CRISP set decentralize clinically annotated tissue repository future collaborative , investigational scientific biomarker testing .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IV stage IIIB ( UICC7 ) patient ineligible curative surgery and/or radiochemotherapy Informed consent later four week start ( palliative ) firstline treatment Age â‰¥ 18 year Able understand willing sign write Informed Consent complete patientreportedoutcome assessment instrument</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>